Would you consider post-BMT maintenance therapy for patients with Ph-like ALL with a JAK2 mutation?

In brief, I would not.

Here is the evidence I have that leads to this conclusion: The activity of targeted therapy for Ph-like ALL has not been established. There are a number of ongoing studies that are attempting to address this (e.g., AALL1521/INCB18424-269; see Tasian et al., ASH 2022). What data...